In the original publication [1], there are three typographical errors (naming errors). Two are in Table 1, and one is in the text (Section 5.4.) as published. The corrected names are written below.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
| Position in the Publication | As Appeared in the Publication | To Be Read as |
| Table 1. Entry 7, Column 2 | Trastuzumab | Dolasynthen B7-H4 Directed ADC |
| Table 1. Entry 7, Column 3 | Auristatin hydroxypropylamide (dolasynthen) | Auristatin F-Hydroxypropylamide |
| Section 5.4. | Trastuzumab-dolasynthen | Dolasynthen B7-H4 Directed ADC |
Reference
- Mukherjee, A.; Bandyopadhyay, D. Targeted Therapy in Breast Cancer: Advantages and Advancements of Antibody–Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs. Cancers 2024, 16, 3517. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).